Looking for relief?
With VTAMA, you may achieve significantly clearer skin
In the 12-week clinical studies, up to 40% of adult patients achieved clear or almost clear skin (compared to 6% on cream with no active ingredient).
Before and After
Behind the Ear
Age: 66 Gender: Male Patient: 1006-001 Study: Phase 4, open-label Intertriginous Plaque Psoriasis (in the skin folds) study
Baseline
Week 1
Week 12
Baseline
Week 4
Week 12
Age: 24 Gender: Male Patient: 1006-02 Study: Phase 4, open-label Head and Neck Plaque Psoriasis study
Baseline
Week 4
Week 12
Age: 75 Gender: Female Patient: 1007-02 Study: Phase 4, open-label Head and Neck Plaque Psoriasis study
Baseline
Week 1
Week 12
Age: 67 Gender: Male Patient: 2030-001 Study: Pivotal study
Baseline
Week 4
Week 12
Age: 56 Gender: Female Patient: 1017-010 Study: Pivotal study
Baseline
Week 4
Week 12
Age: 67 Gender: Male Patient: 2030-001 Study: Pivotal study
Baseline
Week 4
Week 12
Age: 63 Gender: Male Patient: 2014-011 Study: Pivotal study
Baseline
Week 4
Week 12
Take a look at the results! These images show the progress of some patients after using VTAMA for 12 weeks.
Please note that these photos are representative of one area on individual patients treated with VTAMA during the clinical studies. Individual results may vary.
See how clearer skin is possible with once‑daily VTAMA
In the 12-week clinical studies, up to 40% of adult patients achieved clear or almost clear skin (compared to 6% on cream with no active ingredient).
In the 12-week clinical studies, 36% and 48% of patients achieved at least 75% clearer skin while using VTAMA (compared to 10% and 7% using cream with no active ingredient, respectively).
Up to 80% of adult patients saw some level of improvement in their plaques within 12 weeks while using VTAMA (compared to 35% using a cream with no active ingredient).*
*Physician Global Assessment (PGA) score of ≥1-grade improvement from baseline at Week 12.
58% of patients achieved clear or almost clear skin at least once, in a 40-week open-label study.†
†In an open-label study, both the patient and their doctor know which treatment is being used.
VTAMA was proven to be safe and well tolerated for long-term use, as studied up to 52 weeks.
In people treated for plaque psoriasis, the most common side effects included: red raised bumps around the hair pores (folliculitis), pain or swelling in the nose and throat (nasopharyngitis), skin rash or irritation (including itching and redness, peeling, burning, or stinging), headache, and flu.
Adult patients who achieved clear skin while using VTAMA stopped treatment
In a 40-week open-label, long-term study, 312 patients achieved clear skin at least once—and stopped using VTAMA.
Those who achieved clear skin maintained clearer skin for an average of ~4 months, before starting treatment with VTAMA once again.
Ask your doctor if VTAMA might be right for you.
The Science Behind Tapinarof
What's AhR?
Your skin has receptors called aryl hydrocarbon receptors (AhR for short). These receptors play an important role in regulating your skin.
Affected skin with plaque psoriasis
When you have plaque psoriasis, your skin's natural barrier is weakened and there is increased inflammation in your skin.
VTAMA's active ingredient
Tapinarof, the active ingredient in VTAMA, supports the weak areas in your skin by activating AhR.
The specific way in which VTAMA works in plaque psoriasis is unknown.
Strictly Necessary Cookies